



## Add a dose of Nippon India Pharma Fund to your portfolio!

(An open ended equity scheme investing in Pharma sector)

Pharma Sector at reasonable current valuations.

Participation across sub-themes like domestic, international, healthcare services etc


Well diversified multicap portfolio

Contact your Mutual Fund Distributor | Call 1860 266 0111#, 91-22-69259696# (For investors outside India) | Visit [mf.nipponindiaim.com](http://mf.nipponindiaim.com)

### This product is suitable for investors who are seeking\*

- ❖ Long term capital growth.
  - ❖ Investment predominantly in equity and equity related securities of pharma & other associated companies
- \*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

### Nippon India Pharma Fund



Investors understand that their principal will be at Very High risk

### BSE Healthcare TRI



Benchmark Riskometer is at Very High risk

#Charges applicable.

## Investment Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma Sector and other associated companies.

<b>Inception Date</b>	5th June 2004
<b>Fund Manager</b>	Sailesh Raj Bhan
<b>Benchmark</b>	S&P BSE Healthcare TRI
<b>Month end AUM as on May 31, 2024</b>	Rs. 7,160.93 Crs

## Current Investment Philosophy

- ❖ The fund is a combination of large cap and mid cap companies with an aim to provide consistent returns.
- ❖ Investments are spread across all the important segments of the industry – Domestic & International, Branded & Generics, CRAMS (Contract Research & Manufacturing) and Healthcare Services – Insurance, Hospitals, Diagnostics.
- ❖ Relative value within the important sub segments of the market is an important investment parameter.
- ❖ Low capital intensive sector that is less impacted by market volatility with good growth visibility and decent cash flows.
- ❖ Increasing Healthcare awareness, domestic demography driven demand possibilities, emergence of new growth areas – Healthcare services/outsourcing, specialty pharma are key drivers.

## Asset Allocation: As on May 31, 2024

<b>Equities</b>	98.38%
<b>Cash and Other Receivables</b>	1.62%

## Investment Style: As on May 31, 2024

<b>Value</b>	<b>Blend</b>	<b>Growth</b>	<b>Large</b>
			<b>Mid</b>
			<b>Small</b>

## Key Portfolio Attributes: As on May 31, 2024

<b>Sharpe Ratio<sup>5</sup></b>	0.51
<b>Portfolio Turnover (Times)</b>	0.12

**\$Note:** The above measures have been calculated using monthly rolling returns for 36 months period with 6.6% risk free return (FBIL Overnight MIBOR as on May 31, 2024).

Risk factor & Disclaimer: Trading volumes and settlement periods may restrict liquidity in equity and debt investments. Investment in Debt is subject to price, credit, and interest rate risk. The NAV of the Scheme may be affected, inter alia, by changes in the market conditions, interest rates, trading volumes, settlement periods and transfer procedures. The NAV may also be subjected to risk associated with investment in derivatives, foreign securities or script lending as may be permissible by the Scheme Information Document. For further details, please refer Scheme Information Document (SID).

The views being expressed only constitute opinions and therefore cannot be considered as guidelines, recommendations or as a professional guide for the readers. Before making any investments, the readers are advised to seek independent professional advice, verify the contents in order to arrive at an informed investment decision. None of the Sponsor, the Investment Manager, the Trustee, their respective directors, employees, associates or representatives shall be liable in any way for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including on account of lost profits arising from the information contained in this material.

## Top 10 Stock Holdings: As on May 31, 2024

<b>Stocks</b>	<b>Allocation (%)</b>
Sun Pharmaceutical Industries Limited	13.37
Lupin Limited	7.74
Divi's Laboratories Limited	7.52
Cipla Limited	6.27
Apollo Hospitals Enterprise Limited	5.29
Dr. Reddy's Laboratories Limited	4.45
Gland Pharma Limited	4.37
Zydus Lifesciences Limited	3.77
Vijaya Diagnostic Centre Limited	3.59
JB Chemicals & Pharmaceuticals Limited	3.16

**Note:** For complete portfolio, please refer website mf.nipponindiaim.com. Current Portfolio Allocation is based on the prevailing market conditions and is subject to changes depending on the fund manager's view of the equity markets. Sector(s) / Stock(s) / Issuer(s) mentioned above are for the purpose of disclosure of the portfolio of the Scheme(s) and should not be construed as recommendation.

## Sector Update & Outlook

- ❖ Pharma & Healthcare segment appears to be well placed from a fundamental perspective for multiple years of reasonable growth across key areas like:
  - Domestic Demand – boosted by increasing awareness and better penetration, growing proportion of population is in the 50 plus age group
  - Pick up in Exports volumes – non-US markets (Emerging Markets + European Union)
  - Stabilizing US business
  - Increased demand for Healthcare services supported by Insurance penetration, Govt spends
  - Visible improvement in earnings growth
  - PLI (product linked incentives) with an aim to promote self – reliance, backward integration and alternative supply chain to China may drive manufacturing growth in areas like Active Pharmaceutical Ingredients (APIs) etc.
- ❖ Indian Pharma sector is one of the most competitively positioned sectors from India to capture both domestic and global pharma growth.

For change in Fundamental Attributes of Nippon India Pharma Fund w.e.f. July 30, 2021 kindly refer notice cum addendum no. 30 dated June 26, 2021.

**Common Source:** MFI, Bloomberg, NIMF Internal Research



**Mutual Fund Investments are subject to market risks, read all scheme related documents carefully.**